United StatesÚltimas notícias

Creative Realities (NASDAQ:CREX) reported a significant increase in top-line revenue for the first quarter of fiscal 2026, driven primarily by the financial integration of its Cineplex Digital Media acquisition, even as margin compression and one-time structural charges pulled bottom-line metrics into a deficit.

Dan Ives of Wedbush Securities says the Cerebras Systems IPO is a watershed moment for the tech sector. He sees the Nasdaq hitting 30,000 in the next six to nine months. He has more on "Bloomberg Surveillance."

Palvella Therapeutics (NASDAQ:PVLA) reported positive clinical data from its Phase 2 TOIVA trial evaluating its proprietary topical formulation of rapamycin, detailing significant therapeutic benefits for patients suffering from rare vascular skin disorders.

RBC Bearings Incorporated (NYSE:RBC) reported strong financial results for the fourth quarter of fiscal 2026, beating Wall Street expectations as accelerating production rates across commercial aviation and defense programs catalyzed top-line growth.

MiNK Therapeutics (NASDAQ:INKT) reported its first-quarter 2026 financial results and operational milestones, highlighting clinical advancement within its invariant natural killer T (iNKT) cell platform alongside successful balance sheet deleveraging.

US President Donald Trump said he made no commitment to Chinese leader Xi Jinping over Taiwan, and said he would make a decision soon over a planned $14 billion arms deal with the island. Trump's remarks aboard Air Force One came after Xi issued an unusually blunt warning that the two nations could descend into conflict if the Taiwan issue is mismanaged. Bloomberg's Annmarie Hordern reports from Beijing.

Digi Power X (NASDAQ:DGXX) reported a wider net loss for the first quarter of 2026, reflecting the financial impacts of its ongoing structural transition away from legacy business operations and toward high-density artificial intelligence infrastructure.

Immuneering (NASDAQ:IMRX), a clinical-stage oncology company developing innovative medicines targeting the MAPK pathway, reported its first-quarter 2026 financial results and provided a corporate update.

BioXcel Therapeutics (NASDAQ:BTAI) announced that the U.S. Food and Drug Administration has formally accepted a supplemental New Drug Application for its lead neuropsychiatric drug, providing a clear regulatory catalyst as the company manages tightening capital constraints.

Traws Pharma (NASDAQ:TRAW) reported a net loss for the first quarter of 2026 as the company aggressively scaled up investments in its respiratory antiviral pipeline, pivoting away from the profitable metrics recorded in the prior year's opening period.

Protara Therapeutics (NASDAQ:TARA) reported updated 12-month interim data from the Cohort A arm of its Phase 2 ADVANCED-2 clinical trial, demonstrating sustained tumor clearance and a favorable safety profile for its lead oncology candidate.

PowerBank (NASDAQ:SUUN) reported a significant expansion in its underlying profit margins and a strengthened balance sheet for the first nine months of fiscal year 2026, driven by systematic execution of its North American clean energy project pipeline.